Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mosapride sustained release - Daewoong Pharmaceutical

Drug Profile

Mosapride sustained release - Daewoong Pharmaceutical

Alternative Names: DWJ 1252

Latest Information Update: 23 Feb 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daewoong Pharmaceutical
  • Class Antiulcers; Benzamides; Gastrokinetics; Morpholines; Small molecules
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Dyspepsia

Most Recent Events

  • 23 Feb 2022 Discontinued - Phase-III for Dyspepsia in South Korea (PO)
  • 18 Apr 2017 Daewoong Pharmaceutical initiates enrolment in a phase III trial for Dyspepsia in South Korea (NCT03184402)
  • 15 Feb 2017 Chemical structure information added

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top